Wide Ranks

CYBN

Cybin Inc.

10.25

Top Statistics
Market Cap 211 M Forward PE -1.73 Revenue Growth 0.00 %
Current Ratio 41.70 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.4740 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 183 M Total Cash Per Share 9.00 Total Debt 212000
Total Debt To Equity 0.0760 Current Ratio 41.70 Book Value Per Share 14.34
All Measures
Short Ratio 407.00 % Message Board Id finmb_666815486 Shares Short Prior Month 641827
Return On Equity -0.4907 City Toronto Uuid 6060ec65-0298-34e5-9f58-0e67c0de2a6f
Previous Close 10.71 First Trade Date Epoch Utc 1 B Book Value 14.34
Beta 0.8850 Total Debt 212000 Volume 204613
Price To Book 0.7147 Last Split Date 1 B Fifty Two Week Low 6.50
Total Cash Per Share 9.00 Shares Short Previous Month Date 1 B Target Median Price 140.60
Max Age 86400 Recommendation Mean 1.20 Sand P52 Week Change 0.3133
Target Mean Price 145.81 Net Income To Common -78390000 Ask 10.45
Implied Shares Outstanding 20 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 988910 Average Volume10days 988910 Total Cash 183 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0635 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 10.71
Target Low Price 35.12 Gmt Off Set Milliseconds -18000000 Fifty Day Average 10.19
Open 10.75 Free Cashflow -50425752 State ON
Dividend Yield 0.00 % Return On Assets -0.3271 Time Zone Short Name EST
Trailing Eps -6.08 Day Low 10.21 Address1 100 King Street West
Shares Outstanding 19 M Price Hint 2 Target High Price 266.90
Website https://www.cybin.com 52 Week Change -0.4006 Average Volume 340893
Forward Eps -4.83 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 3902.30 % Last Split Factor 1:38 Regular Market Day High 10.73
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 0.0760
Fifty Two Week High 19.84 Day High 10.73 Shares Short 609729
Regular Market Open 10.75 Industry Key biotechnology Bid 10.26
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0305
Operating Cashflow -85425000 Currency USD Time Zone Full Name America/New_York
Market Cap 211 M Is_nasdaq_100 False Zip M5X 1C9
Quote Type EQUITY Industry Biotechnology Long Name Cybin Inc.
Regular Market Day Low 10.21 Held Percent Institutions 0.3661 Current Price 10.25
Address2 Suite 5600 Enterprise To Ebitda -0.4740 Financial Currency CAD
Current Ratio 41.70 Industry Disp Biotechnology Number Of Analyst Opinions 4
Country Canada Float Shares 14 M Two Hundred Day Average 11.74
Enterprise Value 40 M Forward PE -1.73 Regular Market Volume 204613
Ebitda -86204000 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.

The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.

The company is headquartered in Toronto, Canada.